Treatment of LUTS secondary to BPH has evolved from surgical therapy to medical monotherapy, and now combination therapy.
The incidence of emergency department visits rose 36% from 2007 to 2010 in California.
Alpha blockers are the mostly commonly prescribed drugs to treat LUTS secondary to BPH.
No evidence of toxicity for patients given doses of up to 960 mg daily for up to 18 months.
The drug increases the likelihood of a successful trial without catheter.
Small study is the first prospective investigation of this procedure in the U.S.
Most patients maintained very-low-risk disease or had negative follow-up biopsies during a three-year follow-up period.
Older and younger patients showed no differences in morbidity and one-year urinary function.
The procedure may be particularly useful in treatment men with prostates larger than 100 cc.
A BMI of 30 kg/m2 or higher also attenuated prostate volume reduction by dutasteride.
Outcomes similar to HoLEP-treated patients who did not have prior surgery.
Complications occur infrequently, and the most common one is urethral stenosis.
Among diabetic men with benign prostatic hyperplasia, those with BPH had a 79% increased risk of bladder cancer.
Men taking the medications for benign prostatic hyperplasia had a better stone clearance rate after shock wave lithotripsy than men not taking the drugs.
Combined treatment deemed safe for benign prostatic hyperplasia; good functional results over 24 months
Study reveals no significant difference in operative or postoperative complications in patients with and without prior surgery.